Launch of ATMP 2030

Advanced Therapy Medicinal Products (ATMPs) are cutting-edge medicines based on cell, gene, or tissue engineering. The goal of ATMP 2030 is to ensure that Sweden will become a leader in the development and implementation of advanced therapies by 2030.

The focus areas of this initiative are:

  • National coordination and strengthening of the network
  • Increased capacity for the industrial development and manufacture of ATMPs
  • Effective processes for availability of cost-effective ATMPs within Swedish healthcare
  • Increase knowledge and secure future competence needs
  • Organization and financing models for sustainable continuation
Flag of Sweden

This cross-functional collaboration between healthcare, industry, and the authorities is now entering its 2nd phase which aims to close urgent gaps in the Swedish ATMP ecosystem, including establishing hospital ATMP centers and a national infrastructure for commercial development.

To learn about this 2nd phase, register for the online webinar (May 31st at 2-4pm CEST).

Learn more about ATMP 2030 in Swedish or English.

Find out how SCRO can support you in the clinical development of ATMPs.